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LT- A252G
a  b  s  t  r  a  c  t
Background: Rheumatoid arthritis is a widely prevalent autoimmune disorder with suggested
genetic predisposition.
Objectives: The aim of this study is to detect the pattern of genetic polymorphism of methy-
lene  tetrahydrofolate reductase (MTHFR C677 T and A1298 C), transforming growth factor-1
(TGF-1  T869 C) and lymphotoxin- (LT- A252G) in patients having rheumatoid arthritis and
correlate these patterns to disease activity and serum levels of tumor necrosis factor-alpha
(TNF-), B-Cell Activating Factor (BAFF), and osteopontin.
Methods: A total of 194 subjects, 90 controls and 104 patients with rheumatoid arthritis were
genotyped for MTHFR C677 T and A1298 C, TGF-1 T869 C and LT- A252G polymorphisms
using a methodology based on PCR-RFLP. Also serum levels of TNF-, osteopontin and BAFF
were measured by ELISA kits.
Results: The CT genotype and T allele of MTHFR C677 T and GG genotype and G allele of LT-
A252G  are associated with the risk of RA and with higher levels of the pro-inﬂammatory
cytokine, TNF- in patients with rheumatoid arthritis.
Conclusion: Our ﬁndings suggest that there is association between MTHFR C677 T and LT-A252G genes polymorphisms and increased risk of RA in this sample of Egyptian population.
ed by Elsevier Editora Ltda. This is an open access article under the CC©  2016 PublishBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Polimorﬁsmos  dos  genes  metilenotetrahidrofolato  redutase,  fator  de





MTHFR C677 T e A1298 C
TGF-1 T869 C
LT- A252G
r  e  s  u  m  o
Antecedentes: A artrite reumatoide é uma doenc¸a autoimune amplamente prevalente com
sugerida predisposic¸ão genética.
Objetivos: Detectar o padrão de polimorﬁsmo dos genes metilenotetrahidrofolato redu-
tase  (MTHFR C677 T e A1298 C), fator de crescimento transformador 1 (TGF-1 T869 C)
e  linfotoxina- (LT- A252G) em pacientes com artrite reumatoide e correlacionar esses
padrões com a atividade da doenc¸a e os níveis séricos de fator de necrose tumoral alfa
(TNF-),  fator ativador de linfócitos B (BAFF) e osteopontina.
Métodos: Foram genotipados 194 indivíduos – 90 controles e 104 com artrite reumatoide – à
procura de polimorﬁsmos dos genes MTHFR C677 T e A1298 C, TGF-1 T869 C e LT- A252G
com  uma metodologia baseada na PCR-RFLP. Mensuraram-se também os níveis séricos de
TNF-,  osteopontina e BAFF com kits de Elisa.
Resultados: O genótipo CT e o alelo T do MTHFR C677 T e o genótipo GG e alelo G do LT-
A252G  estão associados ao risco de AR e a níveis mais elevados da citocina pró-inﬂamatória
TNF-  em pacientes com artrite reumatoide.
Conclusão: Os achados do presente estudo sugerem que há associac¸ão entre os polimorﬁs-
mos  dos genes MTHFR C677 T e LT- A252G e um risco aumentado de AR nessa amostra da
populac¸ão  egípcia.
































heumatoid arthritis (RA) is a widely prevalent autoimmune
isorder which affects ∼1% of the populations in developed
ountries with women more  frequently affected than men
∼3:1).1 In this disease, the joints are the main target of attack
ith great tendency to joint destruction and consequently
mpairment of all aspects of life quality.2 The exact causes
f the disease are unknown, but environmental factors and
enetic predisposition are involved. Although these factors are
ot sufﬁcient for development of disease, yet they may have a
ole in the heterogeneity of the clinical picture, the response
o treatment and they can be target for therapeutic agents.
olymorphic forms of methylene tetrahydrofolate reductase
MTHFR) gene and some cytokine genes have been studied as
ossible markers of susceptibility, severity, and/or protection
n RA.3
C677 T (Ala 222 Val) and A1298 C (Glu 429 Ala)
re two common genetic polymorphisms of MTHFR gene.
hey are both associated with decrease in the activity
f the enzyme 5, 10-methylenetetrahydrofolate reductase
MTHFR) with lower degree in A1298 C compared to C677 T
olymorphism.4 This enzyme is responsible for the synthe-
is of 5-methyltetrahydrofolate, required for pyrimidine and
urine synthesis and regeneration of methionine from homo-
ysteine.5 Decreased activity of this enzyme results in high
evels of homocysteine which is commonly found in patients
ith rheumatoid arthritis (RA), and is partially responsible
or the high rate of cardiovascular complications in these
ubjects.6
Transforming growth factor-1 (TGF-1) is a growth fac-
or that regulates cellular proliferation, wound healing, and BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
angiogenesis in a cell-speciﬁc manner.7 It is present abun-
dantly in rheumatoid joints and it has anti-inﬂammatory
function because overexpression of this gene reduced arthritis
in an animal model.8 Individuals with TGF-1 polymorphisms
in the coding and regulatory regions have a greater propensity
to develop immune system disorders. TGF-1 (T869 C) poly-
morphism affects the serum levels of TGF-1 and is used as
marker for increased disease risk in several diseases.9
Cytokines play an important role in pathogenesis of RA and
its associated inﬂammatory processes and articular destruc-
tion. This occurs mainly through deviation of balance toward
higher levels of pro-inﬂammatory cytokines on the expense
of anti-inﬂammatory cytokines. Thus, the concentration of
members of pro-inﬂammatory TNF- superfamily have been
directly correlated with disease pathology.10 TNF- is a potent
pro-inﬂammatory cytokine produced mainly by macrophages.
It is considered one of the main inﬂammatory mediators of
joint inﬂammation and destruction in RA by inducing other
inﬂammatory cytokines and stimulating expression of adhe-
sion molecules by ﬁbroblasts.11 Lymphotoxin- (LT-), another
member of the TNF superfamily previously known as tumor
necrosis factor- (TNF-)  induces cell apoptosis and inﬂam-
matory responses upon binding to TNF receptor type 1 and 2
respectively.12 A single nucleotide polymorphism (A252G) was
detected within the ﬁrst intron of LT- gene and it was reported
to increase expression of LT- plasma level.13 The two  alleles
resulting from this single nucleotide polymorphism are desig-
nated LT- (10.5 kb) and LT- (5.5 kb). The LT- (5.5 kb) allele is
associated with higher plasma levels of LT-, lymphoid malig-
nancies and a worse outcome of autoimmune diseases.14Another member of TNF family is B cell activating factor
(BAFF) which can bind B cells stimulating their proliferation
and promoting their survival and consequently helping in
 o l . 2416  r e v b r a s r e u m a t
regulation of both innate and adaptive immune responses.
Deregulation of BAFF has been observed in patients with
autoimmune diseases such as rheumatoid arthritis.15 Osteo-
pontin (OPN) is also a pro-inﬂammatory cytokine which has
immunoregulatory effects in autoimmune diseases and could
be involved in the pathogenesis of RA.16
The aim of this study is to detect the pattern of genetic
polymorphism of MTHFR types (C677 T) and (A1298 C), TGF-
1 (T869 C) and LT- (A252G) in rheumatoid arthritis Egyptian
patients and if there is any correlation of those patterns with
disease activity and serum levels of TNF-,BAFF and osteo-
pontin.
Subjects  e  methods
Subjects  selection
This is a cross sectional observational comparative study that
was conducted in Kasr Al Aini rheumatology unit, Faculty
of Medicine, Cairo University from May to December 2013.
The study was conducted according to the principles of the
Helsinki Declaration and was approved by the local ethics
committee of the Faculty of Medicine of Cairo University.
Informed written consent was obtained from all sub-
jects who participated in this study after explaining the aim
and nature of the study. One hundred and four patients
with rheumatoid arthritis (16 males and 88 females) and
ninety healthy control subjects of matched age and sex were
included in the study. The patients were on regular treatment
with non-steroidal anti-inﬂammatory drugs (NSAID) (n = 42),
methotrexate (n = 88), Prednisone (n = 24), Leﬂunomide (n = 32)
and Hydroxychloroquine (n = 56). Patients were treated by dif-
ferent combinations of the previous drugs. Thorough history
taking and physical examination were done for all patients
and Disease activity score in 28 joints (DAS-28) and Health
Assessment Questionnaire total (HAQ) total were calculated.
Laboratory  assays
Serum BAFF, OPN and TNF- were measured by ELISA kits
obtained from R&D Systems, Minneapolis, MN, for the former
two and from AviBion, Helsinki Finland for TNF- according
to the manufacturer’s protocol.
Molecular  analysis
DNA  extraction
Genomic DNA was extracted from peripheral blood using a QIA
amp  DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s protocol. Genotyping was performed by
polymerase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP).
Genotyping  of  MTHFR  A1298  C17
One set of forward “5′-CTT TGG GGA GCT GAA GGA CTA CTA
C-3′′ and reverse “5′-CAC TTT GTG ACC ATT CCG GTT TG-3′′
primers were used for ampliﬁcation of a fragment of 241 base
pairs and then the ampliﬁed fragment was digested with MboII
enzyme. The PCR proﬁle was: initial denaturation at 95 ◦C for 0 1 6;5 6(5):414–420
5 min, followed by 35 cycles each of 30 s at 94 ◦C, 51 ◦C and
72 ◦C, then for 10 min  at 72 ◦C. The AA genotype produces
two bands of 211 and 30 bp, the CC genotype produces a sin-
gle band of 241 bp (uncut), and AC genotypes produces three
bands of 241, 211 and 30 bp.
Genotyping  of  MTHFR  C677  T18
One set of forward “5′-CAT CCC TAT TGG CAG GTT AC-3′′ and
reverse “5′-GAC GGT GCG GTG AGA GTG-3′′ primers were used
for ampliﬁcation of a fragment of 198 base pairs, and then the
ampliﬁed fragments were digested with HinfI enzyme. The
PCR proﬁle was: initial denaturation at 94 ◦C for 5 min, fol-
lowed by 35 cycles of 30 s each at 94 ◦C, 61 ◦C and 72 ◦C and a
ﬁnal elongation at 72 ◦C for 5 min. The wild CC genotype was
identiﬁed by only a 198 bp fragment, the (TT) genotype by the
175/23 bp fragments and heterozygotes (CT) genotype by both
the 198, 175 and 23 bp fragments.
Genotyping  of  TGF-ˇ1  T869  C  genotypes19
One set of forward primers 5′-TTCCCTCGAGGCCCTCCTA-3′
and reverse 5′-GCCGCAGCTTGGACAGGATC-3′ primers were
used for ampliﬁcation of 294 bp fragments of the TGF-1 gene.
PCR products were then digested by MspA1I enzyme. The
PCR proﬁle was: denaturation at 96 ◦C for 10 min, followed
by 35 cycles of 75 s each at 96 ◦C, 62 ◦C and 72 ◦C, and a ﬁnal
extension at 72 ◦C for ﬁve minutes. The T allele resulted in
4 fragments of 161, 67, 40, and 26 bp. The C allele resulted in
fragments of 149, 67, 40, 26, and 12 bp.
Genotyping  of  LT-˛  (A252G)20
A 782 bp fragment of the intron 1 (+252A/G) of the
LT- gene was PCR-ampliﬁed with the primer set: (for-
ward) “5′-AGAGGGGTGGATGCTTGGGTTC-3′′ and (reverse)
“5′-CCGTGCTTCGTGCTTTGGACTA-3′′. PCR products were
digested with NcoI restriction enzyme. The A allele gives a sin-
gle fragment of 782-bp (not digested). The G allele is digested
into 586-bp and 196-bp bands. The PCR proﬁle was: incubation
for 5 min  at 95 ◦C, followed by 35 cycles of 1 min  at 95 ◦C, 1 min
at 52 ◦C, and 1 min  at 72 ◦C, with a ﬁnal extension of 72 ◦C for
7 min.
Statistical  analysis
Statistical Package of Social Science Software program (SPSS),
version 19 was used to analyze data. Data were summa-
rized using frequency and percentage for qualitative data
or mean and standard deviation for quantitative ones. Chi-
squared analysis was used to test for deviation of genotype
distribution from Hardy-Weinberg. Comparison of patients
and healthy control groups were performed using Chi square
test or Fisher’s exact test for qualitative data and Student t
test and ANOVA test for quantitative ones. Bivariate regres-
sion analysis was used to detect association of different
genetic polymorphic forms with the disease. Receiver Oper-
ating Characteristics (ROC) curve analysis was conducted to
explore the discriminant ability of osteopontin and TNF for RA
patients. p values less than 0.05 were considered statistically
signiﬁcant.
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Table 1 – Patients’ characteristics.
Parameters Min Max Mean ± SD
Age (years) 22.0 70.0 42.7 ± 12.1
Disease duration (month) 6 216 66.7 ± 52.5
Morning stiffness (min) 3.0 120.0 29.9 ± 38.2
Number of swollen joints 0.0 18.0 3.3 ± 5.5

















































Figure 1 – ROC curve showing ability of TNF and
osteopontin in discriminating control from rheumatoid
arthritis patients.ESR 5.0 125.0 36.4 ± 36.0
DAS 28 1.4 7.7 3.9 ± 1.6
esults
atients’ characteristics including age, disease duration, clin-
cal manifestations, disease activity and ESR are shown in
able 1.
Comparison between serum level of Osteopontin, BAFF and
NF- (expressed as mean ± SD) in patients and control groups
howed that serum levels of OPN and TNF- were signiﬁcantly
igher in cases compared to controls (p < 0.001). Serum BAFF
evel showed no statistical difference between patients and
ontrol groups (p = 0.6) (Table 2).
On comparing the ability of TNF and Osteopontin in dis-
riminating control from rheumatoid arthritis patients the
OC curve showed that TNF- has a higher discriminating
bility than OPN with sensitivity (94.2%) and speciﬁcity (84.4%)
t cut off value 15.2 pg/ml. On the other hand, OPN has sensi-
ivity (71.2%) and speciﬁcity (53.3%) at cut off value 5.7 ng/ml
s calculated by ROC curve (Figure 1).
The results of this study showed that the genotype frequen-
ies of all studied cases were in Hardy-Weinberg equilibrium
or MTHFR C677 T & A1298 C and TGF-1 T869 C. As for LT-
 A252G, the genotype frequencies were in Hardy-Weinberg
quilibrium only in control group.
On studying the association between rheumatoid arthri-
is and different polymorphic forms of MTHFR C677 T, MTHFR
1298 C, TGF-1 T869 C and LT- A252G (Table 3). The results
f this study showed signiﬁcant association between rheuma-
oid arthritis and CT genotype, T allele of MTHRF C677 T and
he GG genotype and G allele of LT- A252G. On the other
and, the AC genotype of MTHFR A1298 C showed a protective
ffect from the disease when compared to the wild genotype
A. Moreover, no signiﬁcant association has been detected
etween different polymorphic forms of TGF-1 T869 C poly-
orphism and rheumatoid arthritis (Table 3).
HAQ total showed no association with different polymor-hic forms of MTHFR C677 T polymorphism (2 = 5.5, p = 0.06),
THFR A1298 C (2 = 2.26, p = 0.32), TGF-1 T869 C, (2 = 1.31,
 = 0.52) or LT- (2 =1.1, p = 0.57). Also, disease activity as
Table 2 – Comparison between serum level of osteopontin, BAF
patients and control groups.
Cases (n = 104)
Mean ± SD
Osteopontin (ng/ml) 12.9 ± 10.6 
BAFF (pg/ml) 474.5 ± 151.1 
TNF- (pg/ml) 36.0 ± 14.3 shown by DAS 28 was not associated with polymorphic forms
of all examined genes; for MTHFR C677 T (2 = 0.4, p = 0.81), for
MTHFR A1298 C (2 = 0.69. p = 0.7), for TGF-1 T869 C (2 = 4.27,
p = 0.12) and for LT- (2 = 4.54, p = 0.1).
We  found that serum TNF- level differs signiﬁcantly in
the different polymorphic forms of all tested genes except
MTHFR A1298 C as shown in Table 4. Post Hoc test showed
that serum TNF- is signiﬁcantly higher in CT genotype than
in CC genotype in MTHFR C677 T, p = 0.009, in CT genotype
than that in TT genotype in TGF-1 T869 C, p = 0.005, in GG
genotype when compared to that in AA genotype, p = 0.008,
and AG genotype, p = 0.005, in LT- A252G. There is no signiﬁ-
cant difference in OPN and BAFF serum levels in the different
genotypes of examined genes (Table 4).
Discussion
Although the etiology of RA remains unclear, susceptibil-
ity factors that include environmental and genetic factors
are evident. The genetic factors constitute about 50% of
these factors.3 The pro-inﬂammatory cytokines amplify the
inﬂammatory process and destruction in rheumatoid joints.
Tumor necrosis factor, osteopontin and BAFF are among these
cytokines.3
F and TNF- (expressed as mean ± standard deviation) in
Controls (n = 90)
Mean ± SD
p  value
5.9 ± 2.5 <0.001
489.7 ± 145.6 0.6
8.9 ± 6.3 <0.001
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Table 3 – Association between rheumatoid arthritis and different polymorphic forms of MTHFR C677 T, MTHFR A1298 C,
TGF-1 T869 C and LT- A252G.
Genotype and
allele
Patients Control p OR (95% CI)
n % n %
MTHRF C677 T
CC 46 44.2 64 71.1
CT 50 48.1 22 24.4 0.011 3.16 (1.30–7.69)
TT 8 7.7 4 4.4 0.260 2.78 (0.47–16.5)
C 142 68.3 159 83.3
T 66 31.7 30  16.7 0.028 2.18 (1.09–4.38)
MTHFR A1298 C
AA 46 44.2 20  22.2
AC 34 32.7 56 62.2 0.006 0.26 (0.10–0.69)
CC 24 23.1 14 15.6 0.629 0.75 (0.23–2.45)
A 126 60.6 96 53.3
C 82 39.4 84 46.7 0.383 0.74 (0.42–1.32)
TGF-1 T869 C
TT 18 17.3 20 22.2
CT 68 65.4 36 40.0 0.173 2.10 (0.72– 6.10)
CC 18 17.3 34 37.8 0.390 0.59 (0.18–1.97)
C 104 50 104 58
T 104 50 76 42 0.313 0.73 (0.41–1.29)
LT- A252G
AA  6 5.8 16 28.9
AG 42 40.4 48 17.8 0.252 2.33 (0.55–9.95)
GG 56 53.8 26 53.3 0.021 5.74 (1.31–25.26)
A 54 26 
G 154 74 
In this study, serum levels of TNF- are signiﬁcantly higher
in patient compared to control group. The results regarding
TNF- are coincided with results of previous studies such as
Gheita et al.,21 and Ismail et al.,22 who explained these results
by its vital and central role in the etiology and pathogenesis of
RA, hence TNF inhibitors were the ﬁrst of the biological disease
modifying anti-rheumatic drugs (DMARDs) to be approved for
the treatment of RA and now they are part of the routine
treatment of patients with this disease.23 However, Ebrahimi
et al.,24 reported non-signiﬁcant increase in serum TNF- lev-
els in patients when compared to control group.
Also, our results showed signiﬁcant increase in serum
OPN levels in patients with RA than in healthy control group
which are in accordance with results of Ji et al.,25 Chen
et al.26 who explained these results by the cardinal role
of OPN and its receptors in pathogenesis of RA. So, sev-
eral experimental studies aiming to use OPN as therapeutic
Table 4 – Comparison between serum levels of osteopontin, TN
(n = 194).
Serum osteopontin (ng/ml) 
Geno-type Mean ± SD p M
MTHFR C677 T
CC 8.32 ± 7.75
0.248
19.2
CT 11.24 ± 9.92 28.9
TT 11.62 ± 7.91 25.6
MTHFR A1298 C
AA  12.27 ± 11.30
0.076
23.6
AC 7.79 ± 6.00 20.5
CC 9.293 ± 8.00 28.7
TGF-1 T869 C
CC 6.79 ± 5.99
0.151
22.1
CT 10.54 ± 8.66 27.0
TT 10.91 ± 11.07 14.0
LT- A252G
AA  14.99 ± 16.98
0.075
14.4
AG 9.44 ± 7.86 19.3
GG 8.35 ± 5.53 29.880 44
100 56 0.007 2.28 (1.25–4.18)
target are being performed and the outcomes of these results
are promising.27
On the contrary, the serum BAFF showed no signiﬁcant
difference between both groups which is coming with pre-
vious results of Eldin et al.28 However, Mahdy et al.,29 and
Moura et al.,30 reported signiﬁcant increase in serum BAFF
levels among RA patients especially patients with higher dis-
ease activity and shorter disease duration. This discrepancy
in results may be attributed to different disease activity and
duration in the studied group.
The CT genotype and T allele of MTHFR C677 T are asso-
ciated with RA, higher serum level of TNF-, but they have
no signiﬁcant effect on OPN and BAFF serum levels. On the
other hand, the different MTHFR A1298 C polymorphic forms
were not associated with RA, or serum levels of TNF-, OPN
or BAFF. The AC genotype of MTHFR A1298 C showed pro-
tective effect from the disease. This may be due to higher
F- and BAFF in different genotypes in all studied cases
Serum TNF (pg/ml) Serum BAFF (pg/ml)
ean ± SD p Mean ± SD p
0  ± 15.076
0.031
505.16 ± 149.65
0.1623 ± 19.817 444.67 ± 133.17
2 ± 16.080 486.83 ± 197.19
1  ± 16.05
0.233
486.49 ± 136.9793
0.2338 ± 18.17 480.98 ± 157.43
5 ± 17.85 474.47 ± 151.22
7  ± 11.99
0.018
518.42 ± 164.63
0.1379 ± 19.39 482.25 ± 139.42
4 ± 15.32 429.32 ± 139.09
3  ± 3.62
0.004
525.27 ± 174.13
0.5425 ± 15.45 469.87 ± 135.90
2 ± 19.66 482.71 ± 155.02































































1r e v b r a s r e u m a t o l
ffect of MTHFR C677 T on MTHFR enzyme resulting in
yper-homocysteinaemia and subsequent cascade of cytokine
ctivation. Results of previous studies were heterogeneous;
ome showed no association between risk of RA and different
olymorphic forms of MTHFR C677 T and A1298 C.31,32 Oth-
rs reported association of T allele, but not any of the MTHFR
677 T polymorphic forms with RA.3 Rubini et al.33 reported
ssociation of CC genotype of MTHFR A1298 C but not any
f MTHFR C677 T polymorphic forms with susceptibility to
A in Italian population. This heterogeneity in results may
e attributed to racial variations in allele and genotype fre-
uencies as reported by Hughes et al.,32 who  found signiﬁcant
ncrease in T allele in MTHFR C677 T and C allele of MTHFR
1298 C (independent on disease status) in Caucasians when
ompared to African Americans. Also, a signiﬁcant interaction
etween MTHFR polymorphisms and nutrient/environmental
actors (i.e. folate status, age, smoking and alcohol intake) was
eported.4 Transforming growth factor-1 (TGF-1) is an anti-
nﬂammatory cytokine associated with disease remission, and
n addition has the potential to be pro-inﬂammatory cytokine.
olymorphisms of TGF-1 have been reported to be associ-
ted with variations in the serum levels of TGF-1 and with
everal diseases.34 In this study, the TGF-1 (T869 C) geno-
ypes were not associated with RA. However, the CT genotype
as associated with signiﬁcant increase in serum TNF when
ompared to TT genotype. This is coming with results of the
wo meta-analysis studies done by Zhang et al.35 and Chang
t al.36 which showed no clear association of TGF-1 T869 C
olymorphism and T allele with RA on a worldwide popula-
ion but association was suggested only in the people of Asian
escent. The results of Hussein et al.37 was different as they
ound association of TGF-1 T allele with susceptibility to RA
n Egyptian patients. Our results also showed association of
he G allele and the GG genotype of LT- A252G with RA and
igher TNF- serum levels. These results are in accordance
ith that of Karray et al.38 and Al-Rayes et al.,39 which reported
ssociation between GG and AA genotypes with RA, while GA
enotype was refractory.
From the above we can conclude that CT genotype of
THFR C677 T, AC genotype of MTHFR A1298 C and GG geno-
ype of LT- A252G are associated with increased risk of RA in
gyptian patients.
To our knowledge, this is the ﬁrst study to evaluate simulta-
eously the association of MTHFR C677 T and A1298 C, TGF-1
869 C and LT- A252G polymorphisms with RA and with
ro-inﬂammatory cytokines TNF, BAFF and OPN in Egyptian
atients.
Some limitations were facing this study as it included a
ery broad group of patients regarding disease duration, dis-
ase activity, patients taking different drugs and no mention
as made about rheumatoid factor and Anti-CCP positivity.
he cytokines measurements may vary widely with these fac-
ors and also with other methodology details, such as time
etween the sample is collected and processed, DAS-28, drugs
nd its’ doses when the samples were collected.onﬂicts  of  interest
he authors declare no conﬂicts of interest.
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